Treatment of Cutaneous Leishmaniasis in Patients on Immunosuppressive Therapy (TNF-α Antagonist, Methotrexate, or Prednisone)
Managing cutaneous leishmaniasis in a patient who is concurrently receiving immunosuppressive treatment — including TNF-α antagonists, methotrexate, or prednisone — or who has HIV infection requires a tailored clinical approach distinct from the general population.
Clinical Scenario
In most patients treated with a TNF-α antagonist, methotrexate, or prednisone, the clinical presentation of cutaneous leishmaniasis is similar to that of healthy persons; however, there may be some differences in presentation or course. This immunosuppressed context shapes both diagnostic considerations and the overall management strategy.
Approach Overview
Cutaneous lesions in this population generally respond to antileishmanial treatment. Management of the concurrent immunosuppressive regimen is also a key component of the overall approach — the full protocol specifies how and when this is addressed.
The complete structured regimen — sequencing, options, monitoring criteria, and decision points — is available in the full protocol.
Treatment goal: complete reepithelialization of the cutaneous lesion
References
DOI: 10.1111/jtm.12089
- In most patients treated with a TNF-α antagonist, methotrexate or prednisone, the clinical presentation is similar to that of healthy persons; however, there might be some differences.
- The lesions usually respond well to antileishmanial treatment.
- If possible, immunosuppressive treatment should be discontinued until after the skin lesion has healed and then restarted under close observation.
- Treatment failure is present when reepithelialization is incomplete 3 months after starting therapy.
View source ↗